NIH Awards $8.5 Million for Research on Pharmaceuticals for Children
News Nov 19, 2009
Studying drugs in pediatric populations is challenging because drugs often affect children differently than they do adults. The scarcity of pediatric studies limits the ability of doctors and scientists to predict drug dosing, safety and efficacy in children.
To address this gap, the National Institutes of Health announced 18 grants to help determine outcome measures and increase the likelihood of success of future trials of treatments for children.
The grants were awarded to 17 Clinical and Translational Science Award (CTSA) institutions to support 18 studies of pharmaceutical treatments for children. The CTSA consortium is a national network of 46 medical research institutions working together to improve the way biomedical research is conducted across the country.
The $8.5 million in funding will support studies which focus on three areas critical to health: pediatric cardiology, neonatology and pediatric neurology.
The awards will be administered by the National Center for Research Resources (NCRR) while the funding was provided by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The NCRR and NICHD are part of the NIH.
"These awards exemplify what the CTSA program supports: innovative, transformative and collaborative research," said Barbara Alving, M.D., director of NCRR. "These CTSA institutions are uniquely positioned to deliver outcomes in these studies that may translate into better treatments for children in the future."
The funding is part of NIH's continuing efforts in studying drugs for use in pediatric populations. The Best Pharmaceuticals for Children Act of 2002 established a process to study on-patent and off-patent drugs for children and to improve pediatric therapeutics through collaboration on scientific investigation, clinical study design, weight of evidence, and ethical and labeling issues.
"People of different ages require research outcome measures that are tailored to their size and condition," said Steven Hirschfeld, M.D., Ph.D., NICHD associate director for clinical research. "These studies will fill a critical gap by providing the precision needed to understand outcomes for younger patients who may respond differently than adults, and thereby enhance the quality of pediatric research."
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE